Timing and causative organisms associated with modern inflatable penile prosthesis infection: an institutional retrospective

• Published in: Journal of sexual medicine 2023-01, Vol.20 (1), p.107-112
• Main Authors: Bole Md, Raevti, Habashy Md, Engy, Yang Md, David, Ahmed MBBCh, Mohamed, Trost Md, Landon, Ziegelmann Md, Matthew, Helo Md, Sevann, Kohler Md, Tobias
• Format: Article
• Language: English
• Subjects: Anti-Bacterial Agents - therapeutic use; Diabetes Mellitus; Gentamicins; Humans; Male; Penile Diseases - etiology; Penile Implantation - methods; Penile Prosthesis - adverse effects; Povidone-Iodine; Retrospective Studies; Rifampin
• ISSN: 1743-6095; 1743-6109
• DOI: 10.1093/jsxmed/qdac001

The advent of antibiotic-coated devices has reduced the rate of inflatable penile prosthesis (IPP) infections; however, this may have altered microbial profiles when infections do occur. To describe the timing and causative organisms behind infection of infection retardant-coated IPPs in the context of our institution's perioperative antimicrobial protocols. We retrospectively reviewed all patients undergoing IPP placement at our institution from January 2014 to January 2022. In all patients, perioperative antibiotic administration was congruent with American Urological Association guidelines. Boston Scientific devices are impregnated with InhibiZone (rifampin and minocycline), and all Coloplast devices were soaked in rifampin and gentamicin. Intraoperative irrigation was performed with betadine 5% irrigation prior to November 2016 and with vancomycin-gentamicin solution afterward. Cases involving prosthesis infection were identified, and variables were extracted from the medical record. Descriptive and comparative statistics were tabulated to identify clinical characteristics, including patient comorbidities, prophylaxis regimen, symptom onset, and intraoperative culture result. We previously reported an increased infection risk with Betadine irrigation and stratified results accordingly. The primary outcome was time to infectious symptoms, while the secondary outcome was description of device cultures at the time of explantation. A total of 1071 patients underwent IPP placement over 8 years with an overall infection rate of 2.6% (28/1071). After discontinuation of Betadine, the overall infection rate was significantly lower at 0.9% (8/919) with a relative risk of 16.9 with Betadine (P